Thursday, 19 November 2026
Venture Intelligence News

M&A M&A

Piramal Pharma to acquire remaining 26% stake in CDMO arm Yapan Bio

Source Yapan Bio (opens in a new tab)Business Line (opens in a new tab)BSE Announcement (opens in a new tab)

Mumbai-based publicly listed Piramal Pharma is to acquire the remaining 26% equity stake in Hyderabad-based Contract Development and Manufacturing Organization (CDMO) Yapan Bio Pvt Ltd . Upon the completion of this transaction, Piramal Pharma’s shareholding in Yapan Bio will increase from the current 74% to 100%, turning the firm into a wholly owned subsidiary.Founded in 2019 by Atin Tomar and Nirav Desai, Yapan Bio is a CDMO that provides services for vaccines and biologics.

Company website ↗ (opens in a new tab)